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Purpose
Multiple Myeloma is one of the hematological malig-
nancies that is caused by an unregulated proliferation of
a single clone of plasma cells in the bone marrow lead-
ing to anemia, thrombocytopenia, bone destruction and
pathological fractures. Accumulation of M-protein in
the plasma suppresses normal level of immunoglobulins.
Chemotherapy is based on the combination of alkylating
agents, use of high dose of corticosteroids, combination
of antimitotic agents, proteosome inhibitors and immu-
nomodulators. Large numbers of people with Multiple
Myeloma are not sensitive enough to standard che-
motherapy or develop severe side effects that lead to
termination of conventional treatment. Curcumin is a
polyphenolic compound of turmeric that has diverse
pharmacological effects including anti-inflammatory,
antioxidative, antiproliferative and angiogenic activities.
Several studies showed that curcumin can prevent drug
resistance and increase the effect of several chemothera-
peutic agents.
Methods
We utilized a comprehensive review of mechanisms and
biological activities of curcumin as a chemosensitizer
and anticancerous compound through PubMed and
other databases. Also, we analysed the reports and clini-
cal trials which have examined specific effects of curcu-
min on different malignancies.
Results
The research within the last several years in vitro and in
vivo (animal models) showed that curcumin can sensi-
tize cancer cells to different chemotherapeutic agents
that are commonly used for Multiple Myeloma treat-
ment. Curcumin up regulates caspase family proteins
and down regulates antiapoptotic genes such as Bcl-2
and Bcl-X. The mechanisms by which curcumin may
mediate chemotherapy include down regulation of var-
ious growth regulatory pathways and specific genetic
targets such as NF-kB and COX2. Another property of
curcumin is the ability to activate NRF2 and induce the
expression of antioxidant enzymes that are shown to
protect normal tissue and organs during chemotherapy.
Conclusion
Preclinical studies on Curcumin and chemotherapeutic
agents are expected to lead to clinical trials that will
improve the treatment outcome for the patients with
Multiple Myeloma.
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